CAJ | 학술논문

目的：探讨晚期非小细胞肺癌（NSCLC）组织中BRCA1和TUBB3的表达及其与铂类疗效的关系。方法：采用免疫组化检测66例晚期NSCLC组织中BRCA1和TUBB3的表达，并回顾性分析其表达与化疗疗效之间的关系。结果：BRCA1、TUBB3高表达率分别为34．8％（23/66）、48．5％（32/66）；BRCA1高表达组化疗有效率为30．4％（7/23），低表达组的化疗有效率为67．4％（29/43），两者差异有统计学意义（P＝0．004）；TUBB3高表达组化疗有效率为59．4％（19/32），低表达组的化疗有效率为50．0％（17/34），两者差异无统计学意义（P＞0．05）。结论：BRCA1表达可预测铂类药物敏感性，有利于个体化化疗方案的制定。而TUBB3表达对晚期NSCLC患者接受铂类方案化疗的疗效没有预测价值。
목적：탐토만기비소세포폐암（NSCLC）조직중BRCA1화TUBB3적표체급기여박류료효적관계。방법：채용면역조화검측66례만기NSCLC조직중BRCA1화TUBB3적표체，병회고성분석기표체여화료료효지간적관계。결과：BRCA1、TUBB3고표체솔분별위34．8％（23/66）、48．5％（32/66）；BRCA1고표체조화료유효솔위30．4％（7/23），저표체조적화료유효솔위67．4％（29/43），량자차이유통계학의의（P＝0．004）；TUBB3고표체조화료유효솔위59．4％（19/32），저표체조적화료유효솔위50．0％（17/34），량자차이무통계학의의（P＞0．05）。결론：BRCA1표체가예측박류약물민감성，유리우개체화화료방안적제정。이TUBB3표체대만기NSCLC환자접수박류방안화료적료효몰유예측개치。
Objective To investigate the relationship between the expression of BRCA1,β-tubulin III (TUBB3) and their efficacies with platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods The expression levels of BRCA1 and TUBB3 were detected by immunohistochemistry. The relationship between BRCA1 and TUBB3 expressions and their efficacies were analyzed. Results The high expression rate of BRCA1 was 34.8%, and the efficacy of platinum-based chemotherapy in patients with BRCA1-lower expression is obviously better than that in patients with BRCA1-higher expression. There was a significant difference between these two groups (30.4%vs 67.4%, P=0.004). The effective rate of platinum-based chemotherapy in TUBB3-higher expression group and TUBB3-lower expression group were illustrated no significance (59.4% vs 50.0%, P=0.445). Conclusion Platinum-based chemotherapy is more suitable for the advanced NSCLC patients with lower expression of BRCA1. The expression level of BRCA1 could be used to predict the efficacy of platinum-based chemotherapy in advanced NSCLC patients.